Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

Sponsor
AIDS Malignancy Consortium
Study ID
NCT00310128
Phase
PHASE2
Status
Withdrawn

Conditions

  • AIDS-related Lymphoma
  • Adult Non-Hodgkin's Lymphoma
  • Anaplastic Large Cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • cisplatin — DRUG
  • cytarabine — DRUG
  • etoposide — DRUG
  • methylprednisolone — DRUG
  • rituximab — DRUG
  • yttrium Y 90 ibritumomab tiuxetan — DRUG
  • antibody therapy — PROCEDURE
  • biological therapy — PROCEDURE
  • chemotherapy — PROCEDURE
  • monoclonal antibody therapy — PROCEDURE
  • radiation therapy — PROCEDURE
  • radioimmunotherapy — PROCEDURE
  • radioisotope therapy — PROCEDURE

Study Details

RATIONALE: Drugs used in chemotherapy, such as etoposide, methylprednisolone, cytarabine, and cisplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab and yttrium Y 90 ibritumomab tiuxetan, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them without harming normal cells. Giving more than one drug (combination chemotherapy) together with rituximab and yttrium Y 90 ibritumomab tiuxetan may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving combination chemotherapy together with rituximab and yttrium Y 90 ibritumomab tiuxetan works in treating patients with relapsed or refractory AIDS-related non-Hodgkin's lymphoma.

Key Dates

Start date
Feb 28, 2006
Status verified
Feb 2016

Study Design

Enrollment
0 participants (actual)
Primary purpose
TREATMENT

Related Studies